The up regulation of VEGF through the induction of the hypoxia pathway with mutation of the VHL gene is well accepted in the pathogenesis of ccRCC and has led to the successful development of molecular therapies in the treatment of RCC. This evidence concerns the gene VEGFA and renal cell adenocarcinoma.